Latest Share Chat

REMOVE ADS

Prothena Ord Share Chat (0Y3M)

Prothena Ord Information

Share Price Information for Prothena Ord (0Y3M)

Share Price is delayed by 15 minutes

Get Live Data

8.08 0.00 (0.00%)

Bid:

0.00

Ask:

0.00

Spread: 0.00 (0.00%)

Market Cap: $423.01m

Last checked at -

Intraday Prothena Ord Share Chart

This share is an international stock.

REMOVE ADS

Some Videos You Might Like

What's Hot end of April

28th April 2026

Barclays

Chat Filters

You must be logged in to use filters Click here to login

Post Message

Post a Message

You must be logged in to post Click here to login

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".

By posting on our share chat boards you are agreeing to the following:

You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
- discuss illegal or criminal activities.
- post any confidential or price sensitive information or that is not public knowledge.
- post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
- post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
- post any personal details (e.g. email address or phone number).
- post live price or level 2 updates.
- publish content that is not your original work, or infringes the copyright or other rights of any third party.
- post non-constructive, meaningless, one word (or short) non-sense posts.
- post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
- post any affiliate or referral links, or post anything asking for a referral.
- post or otherwise publish any content unrelated to the board or the board's topic.
- re-post premium share chat posts on regular share chat.
- restrict or inhibit any other user from using the boards.
- impersonate any person or entity, including any of our employees or representatives.
- post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
- If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.

The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.

Please note some users may not behave properly and may post content that is misleading, untrue or offensive.

It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.

Premium and Verified Members

Premium Members are members that have a premium subscription with London South East. You can subscribe here.

London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.

Only showing the five most recent posts. Click here to view the whole thread.

Only showing the five most recent posts. Click here to view the whole thread.

Only showing the five most recent posts. Click here to view the whole thread.

From Markets Insider
Citigroup Reaffirms Their Buy Rating on KBR (KBR)
Feb. 17, 2023, 10:25 AM
In a report released today, Andrew Kaplowitz from Citigroup maintained a Buy rating on KBR (KBR – Research Report), with a price target of $67.00. The company’s shares opened today at $55.68.
According to TipRanks, Kaplowitz is a 5-star analyst with an average return of 14.8% and a 64.58% success rate. Kaplowitz covers the Industrial Goods sector, focusing on stocks such as General Electric, A. O. Smith Corporation, and Atkore International Group.
Currently, the analyst consensus on KBR is a Strong Buy with an average price target of $67.67, which is a 21.53% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $70.00 price target.
Based on KBR’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.63 billion and a net profit of $74 million. In comparison, last year the company earned a revenue of $1.84 billion and had a net profit of $57 million
Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KBR in relation to earlier this year. Most recently, in November 2022, Kelly Douglas Nick, the President of KBR sold 3,456.00 shares for a total of $177,465.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KBR, Inc. engages in the provision of differentiated professional services and technologies across the asset and program life-cycle within the government services and hydrocarbons industries. It operates through the following segments: Government Solutions, Technology Solutions, Energy Solutions, Non-strategic Business, and Other. The Government Solutions segment provides full life-cycle support solutions to defense, space, aviation, and other programs and missions for military and other government agencies. The Technology Solutions segment combines KBR’s proprietary technologies, equipment, and catalyst supply and associated knowledge-based services into a global business for refining, petrochemicals, inorganic, and specialty chemicals as well as gasification, syngas, ammonia, nitric acid, and fertilizers. The Energy Solutions segment provides full life-cycle support solutions across the upstream, midstream and downstream hydrocarbons markets. The Non-strategic Business segment represents the operations or activities which the company intends to exit upon completion of existing contracts. The Other segment includes corporate expenses and general and administrative expenses not allocated to the business segments above. The company was founded on March 21, 2006 and is headquartered in Hous

What a timely top up buy in Janux Therapeutics was $52.65 on 12/4/2024 it was up 10 times from 9th November 2023 when $5.85 a 5 year low , they increased position by 15 % last few weeks when price was around $36 1/4/2024.

36 to 52.65 = 46%

April 23, 2024

The biopharma specialist has made a flurry of major new purchases in recent weeks.

Biopharma hedge funds have been on a buying spree the past several weeks. Many of them reported in regulatory filings that they have initiated positions of at least 5 percent in individual stocks or boosted positions to well in excess of 5 percent of outstanding shares.

No firm, however, has been nearly as aggressive as RA Capital Management. In just the past four weeks, it has filed seven initial 13G or 13D documents indicating new investments of 5 percent or more. It also filed amended documents saying it has added to positions in at least four companies that are now holdings of 5 percent or more. Two of the new positions currently rank among the firm’s top-18 holdings, and three stocks in which RA Capital increased existing stakes were catapulted into the firm’s top eight.

This flurry of activity is unusual among life sciences and biopharma hedge funds, which rarely shuffle their portfolio’s largest positions from quarter to quarter. They are generally more of a buy-and-hold crowd, betting on firms they believe have the next drugs with the potential to receive FDA approval. Of course, given these fledgling companies’ small market caps, it does not take much capital to reach the 5 percent that triggers a 13D or 13G filing.

RA Capital is headed by founder Peter Kolchinsky and managing partner Rajeev Shah. As Institutional Investor previously reported, its hedge fund is up 14 percent for the year through March.

With the recent transactions, three stocks have moved onto the firm’s top-ten list.

Janux Therapeutics is the firm’s fourth-largest long, representing 5.72 percent of RA Capital’s U.S. common stock assets after the stake was boosted by more than 15 percent. The hedge fund firm now owns about 20 percent of the total shares outstanding. It is no stranger to Janux, as it was a major venture capital shareholder before the company went public in 2021. Janux is designing T cell immunotherapies that will kill tumors without impacting healthy tissue.

89bio is the seventh-largest long since RA Capital expanded its stake by nearly 25 percent. The hedge fund now has more than 15 percent of the clinical-stage biopharmaceuticals company, which develops therapies for liver and cardiometabolic diseases.

And Tyra Biosciences is the eighth-largest long after the firm recently lifted its stake by about 45 percent. RA Capital now owns more than 25 percent of the total shares. Tyra describes itself as a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor biology.

REMOVE ADS

Only showing the five most recent posts. Click here to view the whole thread.

Today's News.

Walgreens Boots Alliance (NASDAQ:WBA) Shares Gap Up After Better-Than-Expected Earnings

Written by MarketBeat

January 10, 2025

Walgreens Boots Alliance, Inc. share price gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $9.22, but opened at $10.60. Walgreens Boots Alliance shares last traded at $11.56, with a volume of 26,878,129 shares.

The pharmacy operator reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.13. Walgreens Boots Alliance had a positive return on equity of 14.23% and a negative net margin of 5.85%. The business had revenue of $39.50 billion for the quarter, compared to analysts' expectations of $37.40 billion. During the same quarter in the previous year, the firm earned $0.66 earnings per share. The business's revenue was up 7.6% on a year-over-year basis.

Walgreens Boots Alliance Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Monday, November 18th were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 8.73%. The ex-dividend date was Monday, November 18th. Walgreens Boots Alliance's payout ratio is -9.99%.

Before today.

Several brokerages have commented on WBA. Truist Financial cut their price target on shares of Walgreens Boots Alliance from $13.00 to $10.00 and set a "hold" rating for the company in a report on Monday, October 7th. Royal Bank of Canada decreased their target price on Walgreens Boots Alliance from $13.00 to $9.00 and set a "sector perform" rating on the stock in a research note on Wednesday, December 4th. Morgan Stanley dropped their price target on Walgreens Boots Alliance from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, October 11th. Jefferies Financial Group decreased their price objective on shares of Walgreens Boots Alliance from $19.00 to $9.00 and set a "hold" rating on the stock in a research report on Wednesday, October 23rd. Finally, TD Cowen cut their target price on Walgreens Boots Alliance from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, October 22nd. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Walgreens Boots Alliance currently has a consensus rating of "Hold" and a consensus price target of $12.58.

Only showing the five most recent posts. Click here to view the whole thread.

Today $72.50..... 18th September recent high $91.49

Fell to a 3 month low of $70.32 on news below yesterday , sparking a big fall in markets already nervous of a large AI correction , after last weeks warnings.

The FTSE 100 closed down sharply on Friday, although well above early lows, as investors weighed Thursday's hefty falls on Wall Street sparked by fears surrounding US regional banks.

The FTSE 100 index closed down 81.52 points, down 0.9%, at 9,354.57. It had earlier traded as low as 9,276.91 down 1.6%

The FTSE 250 ended 208.40 points lower, 1.0%, at 21,782.96 while the AIM All-Share shed 17.24 points, 2.2%, to 772.65.

For the week, the FTSE 100 was down 0.8%, the FTSE 250 was 0.1% lower, and the AIM-All Share declined 1.7%.

The Cboe UK 100 ended down 0.9% at 935.14, the Cboe UK 250 closed 1.2% lower at 18,996.60 while the Cboe Small Companies fell 1.2% at 17,508.04.

Wall Street took a tumble on Thursday and shares of regional banks took a hit after Zions Bancorp and Western Alliance said they had been victims of fraud on loans to funds that invest in distressed commercial mortgages.

Zions Bancorp said it would take a USD50 million charge related to a loan issued by its California Bank & Trust division, while Western Alliance said it had begun legal proceedings over a bad loan.

"While everyone has been watching the tech sector for signs of a bubble, it's the banking sector that's the root cause of a minor market sell-off today," said Russ Mould, investment director at AJ Bell.

Mould noted "pockets" of the US banking sector including regional banks have given the market cause for concern.

"This includes Zions flagging an unexpected loss on two loans and Western Alliance alleging a borrower had committed fraud," he added.

But he said the pullback in UK-listed banks will be "sentiment-driven."

"Investors have been spooked and moved to trim positions in the sector, possibly opting to have lower exposure in case a crisis is brewing. There is no evidence of any issues with the London-listed core banking names, but investors often have a knee-jerk reaction when problems appear anywhere in the sector," he added.

Barclays shed 5.7%, while Standard Chartered fell 3.5% and HSBC 2.5%. Lloyds Banking Group and NatWest ended down 2.4% and 2.9% respectively.

ICG, which has exposure private credit and asset backed finance fell 5.5%.

Stocks in New York were lower at the time of the London close. The Dow Jones Industrial Average was down 0.1%, the S&P 500 was 0.3% lower, while the Nasdaq Composite declined 0.6%.

Shares in Zions rallied 2.5% while Western Alliance firmed 0.9% at the time of the London equity market close, although both were well below opening highs.

Gold miners were also prominent fallers in London as the price of the yellow metal retreated from record highs.

Gold traded at USD4,242.28 an ounce on Friday, down from USD4,270.73 on Thursday.

The latest volatility saw Fresnillo fall 11%

Only showing the five most recent posts. Click here to view the whole thread.

JPMorgan buys First Republic Bank after regulators took control as it struggled with high levels of uninsured deposits in the wake of the collapse of Silicon Valley Bank
Regulators seized the bank on Monday and a deal to sell its assets was struck
San Francisco-based First Republic had total assets of $229.1 billion as of April 13

First Republic Bank has been sold to JPMorgan Chase after regulators seized it on Monday, making it the third major bank to fail in two months.
The California Department of Financial Protection and Innovation (DFPI) said it has closed the San Francisco-based bank and agreed a deal to sell its assets after it had failed to come up with a workable rescue plan.
DFPI appointed the Federal Deposit Insurance Corporation (FDIC) as receiver, and said it accepted a bid from JPMorgan Chase Bank to assume all deposits.
'To protect depositors, the FDIC is entering into a purchase and assumption agreement with JPMorgan Chase Bank, National Association, Columbus, Ohio, to assume all of the deposits and substantially all of the assets of First Republic Bank,' the Federal Deposit Insurance Corporation said in a statement.
Last week, First Republic disclosed that it had lost more than $100 billion in deposits in the first quarter, causing its shares to plummet.
First Republic Bank has been sold to JPMorgan Chase after regulators seized it on Monday.
JPMorgan was one of several interested buyers including PNC Financial Services Group, and Citizens Financial Group Inc, which submitted final bids on Sunday in an auction being run by regulators, sources told Reuters news agency.
JPMorgan was one of several interested buyers including PNC Financial Services Group, and Citizens Financial Group Inc, which submitted final bids on Sunday in an auction being run by regulators, sources told Reuters news agency. Pictured: Jamie Dimon, chief executive officer of JPMorgan Chase & Co, who said of the purchase of First Republic: 'Our government invited us and others to step up, and we did'
The bank's stock closed at $3.51 on Friday, a fraction of the roughly $170 a share it traded for a year ago

LOOKS LIKE THIS WAS FOOLISH.
APRIL 28, 2023 10:09 AM
First Republic Bank stock plunges to record low as rescue plan proves elusive
U.S. officials are coordinating talks to rescue First Republic, with the Federal Deposit Insurance Corp., the Treasury Department and Federal Reserve orchestrating meetings about throwing it a lifeline.(Dania Maxwell/Los Angeles Times)
First Republic Bank plunged to a record low as investors sorted through rescue scenarios, none of which is likely to be good for current shareholders.
The San Francisco-based bank gained as much as 6.6% on Friday and then collapsed more than 50% before trading was halted amid speculation that a takeover by regulators, while not the only possibility in play, is becoming more likely.
U.S. officials are coordinating talks to rescue First Republic, with the Federal Deposit Insurance Corp., the Treasury Department and Federal Reserve orchestrating meetings about throwing it a lifeline, Reuters reported, citing unidentified people.
But some of the biggest U.S. banks, which have already contributed $30 billion in deposits to prop up First Republic, have balked at getting more involved and potentially throwing good money after bad, Bloomberg News reported.
The focus has shifted to a U.S. takeover, according to CNBC. For its part, First Republic has acknowledged it’s engaged in discussions with multiple parties about strategic options.

Some of the banks involved in the previous rescue favor the FDIC seizing First Republic and selling it off, Bloomberg reported. Such a resolution, they said, would be cleaner, even if banks lose some money, and some have already taken reserves. But it’s an outcome the FDIC would prefer to avoid in part because of the multibillion-dollar hit to its own deposit insurance fund.
Either scenario is perilous for current stockholders. Analysts have said the existing shares have little or no value, regardless of whether the bank is salvaged by new owners or goes into receivership. The FDIC has specifically said in recent takeovers that shareholders won’t be protected.
First Republic has been under pressure ever since Silicon Valley Bank’s demise last month stoked concerns about the soundness of other regional banks in the U.S. First Republic was left paying more for funding than it earns on many of its assets, meaning it faces what analysts predict will be at least a year of losses.
The bank’s executives emphasized in an earnings report earlier this week that it has ample cash reserves.

Only showing the five most recent posts. Click here to view the whole thread.

Post Message

Latest Share Chat

Prothena Ord Share Chat (0Y3M)

Share Price Information for Prothena Ord (0Y3M)

Intraday Prothena Ord Share Chart

Some Videos You Might Like

What's Hot 24th March 2026

What's Hot 24th March 2026

What's Hot end of April

Post a Message

Premium and Verified Members

Latest Share Chat

Share Price Information for Prothena Ord (0Y3M)

Intraday Prothena Ord Share Chart

Some Videos You Might Like

Share Discussion for Prothena Ord

Post a Message

Premium and Verified Members

Compare Broker Offers

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending